Search research articles
Contact Us
Filters
Showing results (51-60 of 80) with videos related to
Page
of 8
Sort By:
Critical Care (London, England)
|
July 14, 2025
Cardiac index, SvO<sub>2</sub> or pCO<sub>2</sub> gap may determine benefit from ECMO in cardiogenic shock: post-hoc analysis of the multicenter, randomized ECMO-CS trial
Petr Ostadal, Dagmar Vondrakova, Richard Rokyta, et al.
European Journal of Heart Failure
|
August 8, 2024
Extracorporeal membrane oxygenation in the therapy of cardiogenic shock: 1-year outcomes of the multicentre, randomized ECMO-CS trial
Petr Ostadal, Richard Rokyta, Jiri Karasek, et al.
European Heart Journal. Acute Cardiovascular Care
|
September 1, 2024
Do DanGer-SHOCK-like patients benefit from VA-ECMO treatment in infarct-related cardiogenic shock? results of an individual patient data meta-analysis
Uwe Zeymer, Anne Freund, Matthias Hochadel, et al.
Plos One
|
April 25, 2018
Electrocardiogram-synchronized pulsatile extracorporeal life support preserves left ventricular function and coronary flow in a porcine model of cardiogenic shock
Petr Ostadal, Mikulas Mlcek, Holger Gorhan, et al.
Circulation
|
November 6, 2022
Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial
Petr Ostadal, Richard Rokyta, Jiri Karasek, et al.
The Cochrane Database of Systematic Reviews
|
June 17, 2011
Statins for acute coronary syndrome
Noah Vale, Alain J Nordmann, Gregory G Schwartz, et al.
Current Controlled Trials in Cardiovascular Medicine
|
March 26, 2005
Fluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial)[ISRCTN81331696]
Petr Ostadal, David Alan, Petr Hajek, et al.
The Cochrane Database of Systematic Reviews
|
September 2, 2014
Statins for acute coronary syndrome
Noah Vale, Alain J Nordmann, Gregory G Schwartz, et al.
International Journal of Cardiology
|
February 8, 2011
Updated evidence on early statin therapy for acute coronary syndromes: meta-analysis of 18 randomized trials involving over 14,000 patients
Matthias Briel, Noah Vale, Gregory G Schwartz, et al.
American Heart Journal
|
May 7, 2020
Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction-Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial
Hans-Dirk Duengen, Raymond J Kim, Doron Zahger, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 80) with videos related to
Sort By:
Page
of 8
Critical Care (London, England)
|
July 14, 2025
Cardiac index, SvO<sub>2</sub> or pCO<sub>2</sub> gap may determine benefit from ECMO in cardiogenic shock: post-hoc analysis of the multicenter, randomized ECMO-CS trial
Petr Ostadal, Dagmar Vondrakova, Richard Rokyta, et al.
European Journal of Heart Failure
|
August 8, 2024
Extracorporeal membrane oxygenation in the therapy of cardiogenic shock: 1-year outcomes of the multicentre, randomized ECMO-CS trial
Petr Ostadal, Richard Rokyta, Jiri Karasek, et al.
European Heart Journal. Acute Cardiovascular Care
|
September 1, 2024
Do DanGer-SHOCK-like patients benefit from VA-ECMO treatment in infarct-related cardiogenic shock? results of an individual patient data meta-analysis
Uwe Zeymer, Anne Freund, Matthias Hochadel, et al.
Plos One
|
April 25, 2018
Electrocardiogram-synchronized pulsatile extracorporeal life support preserves left ventricular function and coronary flow in a porcine model of cardiogenic shock
Petr Ostadal, Mikulas Mlcek, Holger Gorhan, et al.
Circulation
|
November 6, 2022
Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial
Petr Ostadal, Richard Rokyta, Jiri Karasek, et al.
The Cochrane Database of Systematic Reviews
|
June 17, 2011
Statins for acute coronary syndrome
Noah Vale, Alain J Nordmann, Gregory G Schwartz, et al.
Current Controlled Trials in Cardiovascular Medicine
|
March 26, 2005
Fluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial)[ISRCTN81331696]
Petr Ostadal, David Alan, Petr Hajek, et al.
The Cochrane Database of Systematic Reviews
|
September 2, 2014
Statins for acute coronary syndrome
Noah Vale, Alain J Nordmann, Gregory G Schwartz, et al.
International Journal of Cardiology
|
February 8, 2011
Updated evidence on early statin therapy for acute coronary syndromes: meta-analysis of 18 randomized trials involving over 14,000 patients
Matthias Briel, Noah Vale, Gregory G Schwartz, et al.
American Heart Journal
|
May 7, 2020
Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction-Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial
Hans-Dirk Duengen, Raymond J Kim, Doron Zahger, et al.
Page
of 8